MediWound (MDWD) Misses Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
February 25, 2020 7:01 AM ESTGenerated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA
Initiated U.S. Phase 2 adaptive design study of EscharEx for the treatment of venous leg ulcers
BARDA initiated the procurement of NexoBrid valued at $16.5 million for emergency response
Conference call begins today at 8:30 a.m. Eastern Time
YAVNE, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical... More
